Related Experiment Video
Updated: Mar 21, 2026
03:08
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
1.1K
Targeting lncRNA DSCAM-AS1 for disease diagnosis and therapy.
Li Zhou1, Yizhou Jin2, Zedong Li3
1Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.
Non-Coding RNA Research
|March 20, 2026
Summary
Long non-coding RNA DSCAM-AS1 (DSCAM antisense RNA 1) promotes cancer by regulating gene expression and cellular processes. Its aberrant expression in tumors suggests potential as a diagnostic biomarker and therapeutic target.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Long non-coding RNAs (lncRNAs) are key regulators in biological processes and diseases, especially cancer.
- DSCAM antisense RNA 1 (DSCAM-AS1) is a lncRNA linked to cancer progression.
- DSCAM-AS1 is overexpressed in various cancers, correlating with tumor growth and spread.
Purpose of the Study:
- To review the discovery, characteristics, and regulatory mechanisms of DSCAM-AS1.
- To discuss the clinical relevance of DSCAM-AS1 in cancer diagnosis and therapy.
- To explore DSCAM-AS1's role as a potential biomarker and therapeutic target.
Main Methods:
- Literature review of studies on DSCAM-AS1.
- Analysis of DSCAM-AS1's molecular functions and regulatory pathways.
- Evaluation of DSCAM-AS1's association with cancer types and clinical outcomes.
Main Results:
- DSCAM-AS1 acts as an oncogene through multiple mechanisms, including transcriptional regulation, ceRNA activity, and alternative splicing modulation.
- It interacts with hnRNPL to affect RNA processing.
- DSCAM-AS1 exhibits cancer- and isoform-specific expression patterns.
Conclusions:
- DSCAM-AS1 is a significant oncogenic lncRNA with diverse regulatory roles in cancer.
- Its expression patterns indicate potential as a diagnostic and prognostic biomarker.
- DSCAM-AS1 represents a promising target for novel cancer therapies.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
02:30siRNA - Small Interfering RNAs
19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K